Treatment of HER2+ and Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
|
|
- Samantha McCoy
- 5 years ago
- Views:
Transcription
1 Treatment of HER2+ and Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
2 Disclosure I have nothing to disclose. Off Label/Investigational Discussion In accordance with Annenberg Center policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations.
3 Which of the following statements about triple negative breast cancer (TNBC) is true? 1. A preferred approach for a high-risk TNBC is to add platinum chemotherapy to an anthracycline- and taxane-based adjuvant regimen 2. Anti-PD-1 monotherapy is a highly active therapy for pretreated metastatic TNBC 3. For metastatic TNBC, carboplatin chemotherapy is superior to docetaxel if there is an associated BRCA mutation 4. Neoadjuvant carboplatin or cisplatin reduces risk of distant recurrence for TNBC. 5. The PARP inhibitor, olaparib, improves survival in stage IV, TNBC with BRCA mutations
4 45 yo with 1.6 cm high grade HER2 3+, ER+, PR- cancer with 0/3 sentinel nodes What would you recommend for adjuvant therapy? AC-TH TCH TCHP TH Hormonal therapy + trastuzumab
5 Chemotherapy versus Trastuzumab + Chemotherapy in HER2+ MBC Chemotherapy (AC/paclitaxel) Chemotherapy plus trastuzumab P value Response Rate 32% 50% <0.001 PFS 4.6 months 7.4 months <0.001 OS 20.3 months 25.4 months Slamon et al, NEJM 2001
6 Why Has anti-her2 Therapy Been Better Than Expected? Limitations in initial pivotal trial Inadequate screening test High rate of cardiac toxicity Recognition of the importance of HER2 suppression after progression oncogene addiction Development of additional anti-her2 agents
7 Proposed Mechanism of Pertuzumab/Trastuzumab Synergy HER2 HER2 HER2 HER 3 II II II II Trastuzuma b Pertuzumab
8 First-Line Setting: CLEOPATRA: Phase III Trial of Docetaxel + Trastuzumab + Placebo vs Pertuzumab HER2-positive MBC (53% no prior chemo 10% prior trastuzumab) 1:1 N=800 End points PFS and OS quality of life biomarker analysis Docetaxel + trastuzumab + placebo Docetaxel + trastuzumab + pertuzumab Only 10% had prior trastuzumab in adjuvant setting
9 HR % CI = 0.56, 0.84 p = OS (%) n at risk Ptz + T + D Pla + T + D CLEOPATRA: Final OS Analysis Median follow-up 50 months (range 0 70 months) months Time (months) Δ 15.7 months Ptz + T + D Pla + T + D 56.5 months Swain et al, ESMO 2014 and NEJM 2015 The 56.5-month median OS was unprecedented and established the role of pertuzumab in the first-line metastatic. Improvement in OS is larger than the PFS benefit.
10 T-DM1 Selectively Delivers DM1 to HER2-Positive Tumor Cells HER2 T-DM1 binds to the HER2 protein on cancer cells Receptor-T-DM1 complex is internalized into HER2-positive cancer cell Potent antimicrotubule agent is released once inside the HER2-positive tumor cell
11 EMILIA: T-DM1 vs Capecitabine/Lapatinib in Second Line Setting Proportion progression-free Median (mos) No. events Cap + Lap T-DM Stratified HR=0.650 (95% CI, 0.55, 0.77) P< Second interim analysis confirmed a statistically significant benefit in overall survival with T-DM Time (mos) Blackwell et al, NEJM 2012
12 Survival Advantage T-DM1 vs. Physician Choice Krop et al, Lancet Oncology 2017
13 MARIANNE Progression-Free Survival HT T-DM1 T-DM1+P Median PFS (mo.) Events (no.) Stratified HR vs HT 0.91 ( ) P= ( ) P=0.14 Progression-Free Survival (%) HT T-DM1 T-DM1+P Stratified HR vs T-DM ( ) No significant difference among the arms CLEOPATRA PFS 18 mo No. at Risk HT T-DM1 T-DM1+P Time (mo.) Ellis et al, ASCO 2015
14 HER2-Directed Therapy with Trastuzumab +/- Pertuzumab in Combination with Hormonal Therapy? Progression Free Survival Analysis TAnDEM (Anastrozole vs Anast/Trastuzumab) N=207, improved PFS, not OS PFS EGF30008 (Letrozole vs Let/Lapatinib) N=219 HER2+, improved PFS, not OS TTP OS Rimawi, SABCS 2016
15 Treatment Approach For Patient Presenting With HER2+ MBC in 2017 First Line: Taxane + Trastuzumab + Pertuzumab Second Line: TDM-1 Third, Fourth.Line Capecitabine + Lap Capecitabine + Trast Vinorelbine + Trast Lapatinib + Trast Other chemo + Trast Endocrine Therapy + Trast +/- Pertuzumab Exception: Patients with ER+/PR+ disease can be treated up front with hormonal therapy generally with anti-her2 therapy
16 CNS Relapse in HERA 1 Year Trastuzumab Observation Overall Number of Patients CNS as 1 st Event 37 (2%) 32 (2%) 69 (2%) Other Site as 1 st Event 326 (19%) 421 (25%) 747 (22%) Patients For Whom Questionnaires Were Returned (of 481) Number of Patients Died with CNS Relapse 98 (47%) 98 (57%) 196 (53%) Pestalozzi et al, Lancet Oncol 2013
17 Lapatinib + Capecitabine is an Active Regimen in Refractory CNS Disease Study Lin 2009 n=237 Single agent lapatinib RR 6% Lin 2009 n=50* Metro 2011 N=30 Sutherland 2010 n=33 Regimen Lapatinib Lapatinib + capecitabine Other drugs in pipeline for CNS disease: neratinib, ONT/ARRY-380 Lin 2011 N=13 Method Volumetric Volumetric WHO RECIST Volumetric* CNS ORR, n (%) 15 (6) 10 (20) 7 (32) 7 (21) 5 (38) CNS SD, n (%) 88 (37) 6 (27) 19 (58) PD, n (%) 108 (46) 9 (41) 6 (18) PFS/TTP, mo (range) 2.4 (2 3) 3.7 (1 8) 5.1 (4 7) 5.5 (4 5) OS, mo (range) 6.4 (5 8) 11 (4 18) 1. Lin NU, et al. Clin Cancer Res 2009;15: ; 2. Metro M, et al. Annal of Oncol 2011;22: ; 3. Sutherland S, et al. Br J Cancer 2010;102: ; 4. Lin NU, et al. J Neurooncol 2011.
18 CNS Response to T-DM1 Pre-T-DM1 Post-T-DM1 Now multiple reports of CNS regression J Neurooncol (2014) 116:
19 Therapy for Stage I-III HER+ Disease
20 Overall Survival Joint Analysis of AC-T +/- Trastuzumab Perez et al, JCO 2014
21 Disease Events in Joint Analysis (with extended follow-up) AC-T (n=2018) AC-TH (n=2028) First Event Local Recurrence Distant Recurrence Contralateral Other malignancy Death w/o disease Perez et al, JCO 2014
22 % alive and disease-free BCIRG-006 DFS Final Analysis (10.3yrs) AC-T AC-TH TCH Patients Events HR (95% C.I.) P (reference) ( ) < ( ) Trastuzumab-containing regimens remain superior at 10y follow-up No formal comparison of anthracycline containing vs not Despite benefits of trastuzumab, 25% of patients have events before 10 years still room for improvement 74.6% 73.0% 67.9% Time (months) Slamon et al, SABCS 2015
23 ALTTO Trial: DFS Analysis No statistically significant benefit from Lapatinib MFU = 4.5 yrs * ** * 97.5% CI **p-value required for statistical significance Piccart et al, JCO 2016
24 Can We Improve in the Adjuvant HER2+ Setting? ExteNet: Study Design HER2+ breast cancer (local) Prior adjuvant trastuzumab & chemotherapy Lymph node /+ or residual invasive disease after neoadjuvant therapy ER/PR + or N=2880 1:1 randomization Neratinib x 1 year 240mg/day Placebo x 1 year 2-year follow-up for idfs 5-year follow-up for idfs 5 + year survival A sizeable minority still experience recurrences in spite of chemotherapy plus trastuzumab. HERA did not support longer duration Trastuzumab. Primary endpoint: invasive disease-free survival (idfs) at 2 years (4 years after treatment completion) Complicated study with many amendments
25 Adjuvant Extended Neratinib: Improvement in DFS with Greater Effect in HR+ than HR- Chan et al, Lancet Oncology 2016
26 APHINITY Schema S U R G E R Y N=4800 Central confirmation of HER2 status ACT or TCH trastuzumab + pertuzumab* x 1 year ACT or TCH trastuzumab + placebo* x 1 year Population: Node + or high risk node negative *antibody therapy started with taxane
27 APHINITY Invasive Disease Free Survival Analysis (Primary Endpoint) von Minckwitz et al NEJM 2017
28 APHINITY: By Nodal Subgroups +3.2% -0.5% Node Positive Node Negative Also greater impact in ER- than ER+
29 Pertuzumab For All? Node negative...no Node positive...generally yes (about 3% benefit) ER+...Maybe not if only 1-3 nodes ER-...Generally yes, unless node neg
30 The Standard Approach for Moderate to High Risk will Change in Spite of Recent Findings More biologic agents will be incorporated into early stage disease Probably less chemotherapy Greater individualization of treatment approach Can the clinical trials keep pace with scientific discovery? Will we be prevented from moving forward in the clinic because of older trials which may not be relevant?
31 Risk in Node Negative HER2+ Tumors Shown Below Risk in Patients with T1a and T1b HER2: Gonzalez-Angulo, JCO 2009 About 15% risk of relapse in small node-negative tumors in most worrisome dataset * endocrine therapy permitted Other series of T1a/b less worrisome Clearly, increased risk in T1c HER2+ cancers Given lower risk, and significant benefits of trastuzumab, a less intensive chemotherapy regimen may be most appropriate
32 APT: Study Design HER2+ ER+ or ER- Node Negative < 3 cm Enroll P P P P P P P P P P P P T T T T T T T T T T T T PACLITAXEL 80 mg/m 2 + TRASTUZUMAB 2 mg/kg x 12 N=410 T T T T T T T T T T T T T FOLLOWED BY 13 EVERY 3 WEEK DOSES OF TRASTUZUMAB (6 mg/kg)* Tolaney et al, NEJM 2015
33 Disease-Free Survival Events with Median Followup of 7 Years DFS Event N (%) Time to event [months; mean(range)] Any recurrence or death 23 (5.7) Local/Regional Recurrence* Ipsilateral axilla (HER2+) Ipsilateral breast (HER2+) New Contralateral Primary Breast Cancer HER2+ HER2- Unknown 5 (1.2) (1.5) (12-54) 51 (37-65) (12-59) 87 (84-90) Distant Recurrence 4 (1.0) 49 (27-63) Death Non-breast cancer related 8 (2.0) 58 (13-71) Tolaney et al, ASCO 2017
34 APT: Updated Recurrence Free Interval RFI Events Invasive Local/Regional Recurrence Distant Recurrence Point Est. 95% Conf. Interval No. of events 3-yr RFI 99.2% 98.4% to >99.9% 3 5-yr RFI 98.1% 96.8% to 99.5% 7 7-yr RFI 97.5% 95.9% to 99.1% 9 Death from Breast Cancer Tolaney et al, ASCO 2017
35 ATEMPT Trial Schema Stage I HER2+* ER+ or ER- R 3 Trastuzumab-DM1 q3weeks X17 N=375 PS 0-1 Adequate organ fx 1 Paclitaxel + Trastuzumab x12 Trastuzumab q3weeks x13 N=500 ACCRUAL COMPLETED 2016 N=125 All HER2 testing centrally confirmed Adjuvant endocrine therapy can be initiated after completion of 12 weeks of therapy Adjuvant radiation therapy can be administered concurrently with study treatment. PI: Sara Tolaney, MD, MPH
36 Neoadjuvant Therapy for HER2+ Disease Neoadjuvant therapy should never be given unless decision already made that some form of systemic therapy should be administered in general not a question with HER2+ disease Leads to less extensive breast and axillary surgery Any of of the standard adjuvant regimens can be given outside of trial Appropriate for most patients with stage II/III disease
37 Standard Neoadjuvant Approaches THP Surgery AC THP AC Surgery TCHP Surgery There may be some situations where one does not need pertuzumab.( i.e. 3.5 cm ER+, clinically node negative)
38 Activity of Preoperative Dual HER2 Blockade: Pathologic Response Rates In NEOSPHERE TH TP THP HP ITT (Overall) 29% 24% 46% 17% ER- 37% 30% 63% 27% ER+ 20% 17% 26% 6% Gianni et al, Lancet 2012
39 A Design to Decrease Treatment, Assess Resistance, and Test New Therapies Target Population Highly Active Targeted Therapy pcr No pcr Limited therapy and follow Sample size will depend on confidence intervals for phase II study of CR patients and phase III of high risk patients (almost certainly < 2000) Comprehensive Tissue/Blood Collection and Analysis Standard Treatment Experimental Treatment
40 The Challenge of HER2 Testing Relatively straightforward most of the time, however confusion can arise from: Testing variability (pre/post testing) Biologic heterogeneity (probably the major issue) Clinical HER2 positivity FISH > 2.0 IHC 3+ HER2 gene copy number > 6 Two equivocal results do not equal one positive result! Oncotype Dx should not be used to assess HER2 Requires close collaboration with pathology and selective retesting
41 THE CHALLENGE OF TRIPLE NEGATIVE BREAST CANCER
42 Timing of TNBC Recurrence is Early Rates of distant recurrence following surgery in triple-negative vs other breast ca Dent et al, Clin Cancer Res 2007
43 Site of 1 st TNBC Recurrence in NCCN Triple Negative vs Luminal HER2+ vs Luminal Site OR (95% CI)** p OR (95% CI) p Distant vs Locoregional 1.33 (1.00, 1.78) (0.84, 1.56) 0.39 Lung vs Other 2.27 (1.50, 3.43) < (1.05, 2.60) 0.03 Brain vs Other 5.32 (2.85, 9.91) < (2.93, 10.43) <0.001 Bone vs Other 0.23 (0.16, 0.33) < (0.28, 0.53) <0.001 Liver vs Other 1.06 (0.69, 1.62) (1.12, 2.52) 0.01 *Analysis based on cohort of 1,235 patients with documented recurrence (TN, n=408; HER2+, n=341; Luminal, n=486). Luminal cohort used as the referent group for all analyses. **OR=odds ratio; CI=confidence interval; Other refers to any/all other distant/locoregional site Lin et al, ASCO 2009
44 The Challenge of Advanced TNBC In patients with TNBC, recurrences: tend to occur early commonly involve lung and CNS are associated with poor survival Better therapeutic options are desperately needed Strategies to consider: new chemotherapy approaches targeted options
45 45 Chemotherapy Options per NCCN
46 Is there a Selective Advantage for Platinum in TNBC? Sledge (JCO 1988) reported 47% response rate in first line metastatic disease Abandoned for many years because of concerns about toxicity largely replaced by taxanes Renewed interest in patients with TNBC due to DNA crosslinking mechanism of action Data from neoadjuvant studies supports activity in TNBC, with pcr rates 20-70% Greatest activity seen in BRCA carriers Sledge et al, JCO 2008; Silver et al JCO 2010; Gronwold et al, ASCO 2009
47 100 TNT Trial: 1 st Line Carboplatin vs Docetaxel in Metastatic TNBC % patients progression free Median PFS: Carboplatin: 3.1 mths (95% CI = 2.5 to 4.2) Docetaxel: 4.5 mths (95% CI = 4.1 to 5.2) Restricted mean survival to 15 mths: Carboplatin: 4.8 mths Docetaxel: 5.2 mths Absolute difference: -0.4 (95% CI -1.1 to 0.3) p = 0.29 Carboplatin = 181 /188 Docetaxel = /188 Months from randomisation Tutt et al, SABCS 2014, Nature Medicine in press 47
48 % patients progression free 100 TNT Trial: Docetaxel vs Carboplatin in TNBC: Influence of BRCA Mutation Status Carboplatin + BRCA1/2 mutated Carboplatin + BRCA1/2 not mutated Docetaxel + BRCA1/2 mutated Docetaxel + BRCA1/2 not mutated 10 17/ / Months from randomisation Interaction Term for treatment & BRCA 1/2 status p = 0.03 Tutt et al, SABCS 2014, Nature Medicine in press 48
49 PARP Inhibition: Synthetic Lethality Iglehart and Silver, NEJM 2009 Inhibition of Poly(Adenosine Disphosphate [ADP]-Ribose) Polymerase 1 (PARP1) in setting of loss of BRCA1 or BRCA2 function (i.e. deficient homologous recomb) leads to cell death
50
51 Primary endpoint: progression-free survival by BICR
52 Objective response by BICR Presented By Mark Robson at 2017 ASCO Annual Meeting
53 Study Design: EMBRACA Patients with locally advanced or metastatic HER2-negative breast cancer and a germline BRCA1 or BRCA2 mutation* Stratification factors: Number of prior chemo regimens (0 or 1) TNBC or hormone receptor positive (HR+) History of CNS mets or no CNS mets Phase 3, international, open-label study randomized 431 patients in 16 countries and 145 sites Primary endpoint Progression-free survival by RECIST by blinded central review Key secondary efficacy endpoints Overall survival (OS) ORR by investigator Safety Exploratory endpoints Duration of response (DOR) for objective responders Quality of life (QoL; EORTC QLQ-C30, QLQ-BR23) Abbreviations: CNS, central nervous system; EORTC, European Organisation for Research and Treatment of Cancer; HER2, human epidermal growth factor receptor 2; mets, metastases; PO, orally (per os); QLQ-BR23, Quality of Life Questionnaire breast cancer module; QLQ-C30, Quality of Life Questionnaire Core 30; R, randomized; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1; TNBC, triple-negative breast cancer. *Additional inclusion criteria included: no more than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease; prior treatment with a taxane and/or anthracycline unless medically contraindicated. HER2-positive disease is excluded. Physician's choice of therapy must be determined prior to randomization. (NCT ) R 2:1 Talazoparib 1 mg PO daily Treatment (21-day cycles) continues until progression or unacceptable toxicity Physician's choice of therapy (PCT) : capecitabine, eribulin, gemcitabine, or vinorelbine Litton et al, SABCS 2017
54 Primary Endpoint: PFS by Blinded Central Review TALA Overall PCT TALA (n = 287) Overall PCT (n = 144) Events, no. (%) 186 (65%) 83 (58%) Median, mo (95% CI) 8.6 (7.2, 9.3) 5.6 (4.2, 6.7) Hazard ratio, 0.54, 95% CI, 0.41, 0.71 P <.0001 Median follow-up time: 11.2 months Litton et al, SABCS 2017
55 Interim OS Analysis: Secondary Endpoint TALA Overall PCT TALA (n = 287) Overall PCT (n = 144) Events, no. (%) 108 (38%) 55 (38%) Median, mo (95% CI) 22.3 (18.1, 26.2) 19.5 (16.3, 22.4) Hazard ratio, 0.76, 95% CI, 0.54, 1.06 P =.105 Survival Probability at: TALA (n = 287) Overall PCT (n = 144) Month 24, % (95% CI) 45% ( ) 37% ( ) Month 36, % (95% CI) 34% ( ) 0%
56 PARP Inhibition in BRCA1+ and Sporadic TNBC 100 Randomized phase II olaparib in sporadic TNBC and known BRCA mutation carriers: % change from baseline TNBC BRCA TNBC non-brca Non-TNBC BRCA Gelmon K, Lancet Oncology 2011 Clinical data to date: Small trials of olaparib, veliparib encouraging in BRCAassociated, not encouraging in sporadic TNBC TNBC alone does not select for BRCA1 dysfunction
57 IMMU-132 Target: Trop2 (EGP-1) Pan-epithelial cancer antigen (related to EpCAM) 80% of patients have moderate to strong expression of Trop-2 by immunohistology; therefore, this is not used for patient selection Prognostic marker in several cancer types Linker: ph sensitive linker (CL2A) Cytotoxic: SN-38 (Irinotecan active metabolite) 7.6 drug molecules/igg Dose schedule: 10 mg/kg days 1 and 8 of 21-day cycles 57
58 Bardia et al, SABCS 2015
59 Other Antibody Drug Conjugates in Development for TNBC CDX-011 (glembatumumab vedotin) Target: GPNMB, Cytotoxic- monomethyl-aurostatin E (MMAE) EMERGE study Ph2 CDX-011 vs Investigator Choice In TNBC with high GPNMB (16 total): ORR 33% SGN-LIV1A Target: LIV-1, transmembrane protein in 65% TNBC Ph1 in breast ca ongoing PF Target: EFNA4 59 Yardley, SABCS 2012
60 20% express PD-L1 Immunotherapy for TNBC: Why Target PD-L1 in TNBC? Robust presence of tumor infiltrating lymphocytes (TILs) High TILs are an independent predictor for pcr/response to chemotherapy High TILs are associated with increased PD-1 expression in TNBC May suggest sensitivity to immune directed therapies Higher mutational load than other breast cancer subtypes Ibrahim E et al, Br Ca Res Treat, 2014; Denkert C et al, JCO, 2010, 2014, 2015
61 Early Success in Checkpoint Blockade Have Been Biased Towards Tumors with High Rates of Somatic Mutation Lawrence et al, Nature 2013
62 Anti PD-1 Ab Pembrolizumab in TNBC: KEYNOTE-012: Waterfall Plot of Response ORR: 18.5%, Median response range weeks 3/5 responders 11 months -Heavily pretreated TNBC -Required tumors to be PD-L1 positive (58% of all screened were PD-L1 +) -Most common toxicities: arthralgia, fatigue, mylagia, nausea (all G1-2) Nanda, SABCS 2014, JCO 2016
63 Ph 1b Atezolizumab + nab-paclitaxel in TNBC Enrolled 24 patients, atezolizumab 800 mg q 2 weeks, nab-paclitaxel 125 mg/m2 weekly 3/1 schedule Responses see in both PD-L1 positive and negative tumors Adams et al, SABCS 2015
64 WHAT IS OPTIMAL THERAPY FOR EARLY TNBC?
65 A Sequential Antracycline-Taxane Combination is the Standard of Care for Moderate-Risk TNBC NSABP-B30 AC-T x 8 vs AT x 4 vs TAC x 6 POSSIBLE REGIMENS AC-paclitaxel (dose dense) AC-weekly paclitaxel AC-docetaxel (every 3 weeks) FEC-docetaxel Swain SM et al. N Engl J Med 2010;362:
66 Pooled Analysis of Dose Dense vs Not Recurrence by ER status ER Negative ER Positive This AACR-SABCS 2017 presentation is the intellectual property of the authors/presenters. Contact for permission to reprint and/or distribute. Grey et al, SABCS 2017 For EBCTCG
67 ABC Trials Schema (nee TC/TAC, B-46I, B-49) Node+ or High Risk Node-Negative Stratification Variables Number of + Nodes (0, 1-3, 4-9, 10+); Hormone Receptor (ER or PgR+, Both Negative) ARM 1 (TaxAC Options) ARM 2 (TC) A TAC q 3 wk TC q 3 wk B AC q 3 wk PTX q 1 wk C AC q 2 wk PTX q 1 wk Arm 1 Options Per Study USOR A only NSABP B-46I/USOR A only NSABP B-49 - investigator choice 1A-1D D AC q 2 wk PTX q 2 wk Endocrine therapy for ER+ or PgR+ patients for minimum of 5 years Designed to prove non-inferiority of non-anthracycline arm Blum et al, ASCO 2016
68 ABC Trials: Invasive Disease Free Survival 100 Alive and Inv. Disease-free (%) yr Treatment N Events IDFS TC % Δ=2.5% TaxAC % HR=1.23, 95% CI ( ) P= Years from Randomization Observed HR on initial 334 events Exceeded pre-specified threshold for futility (> 1.18) > not non-inferior
69 ABC Trials: IDFS by Hormone and Nodal Status Exploratory Analysis Pts TaxAC TC Events TaxAC TC 4 yr IDFS TaxAC TC 4 yr IDFS Delta HR (95% CI) ER/PgR (-) N % 1.31 ( ) 1-3 N % 1.58 ( ) 4+ N % 1.34 ( ) ER or PgR (+) N % 0.69 ( ) 1-3 N % 1.14 ( ) 4+ N % 1.46 ( ) Suggests all groups aside from ER+ N0 benefit from A-containing regimens, especially ER- N+ Presented by: Joanne L. Blum, MD,
70 Should Stage Affect the Choice of of a Treatment Regimen? What is the optimal treatment for small, node negative TNBC tumors?
71 Outcome in National Comprehensive Cancer Network Distant Relapse Free Survival HR-HER2- No chemotherapy Chemotherapy T1a = 74 T1b = 94 T1a = 25 T1b = 170 T1a 5- year estimate : 93% (84-97) T1b 5-year estimate : 90% (81-95) T1a 5- year estimate : 100% T1b 5-year estimate : 96% (90-98) Vaz-Luis et al. JCO 2014;32:
72 Options for Stage 1 Disease Chemotherapy treatment options for low risk disease: 1) simple regimen (AC, TC, CMF) 2) sequential anthracycline/taxane Enthusiasm for Chemotherapy Possible Regimens Microinvasion only Virtually none --- T1a Low to moderate Simple T1b Moderate to high Simple T1c High Simple or selectively sequential approach
73 Is There a Role for Platinum Chemotherapy in the Neo/Adjuvant Management of Triple Negative Breast Cancer?
74 Randomized Trials of Preoperative Platinum Chemotherapy for TNBC GeparSixto Schema GerparSixto pcr: platinum vs not CALGB Schema CALGB pcr: platinum vs not Sikov et al. JCO 2015;33:13-21; von Minckwitz et al. Lancet Oncology, May 2014
75 Does Addition of Preoperative Platinum Improve Survival Outcomes for TNBC? GeparSixto 3Y DFS: Improved with Carbo CALGB Y EVS: Not Improved with Carbo Mixed results on survival benefits from preop platinum in TNBC Achieving pcr is a good surrogate for long-term outcomes on a patient level No evidence that pcr rates can be used as a surrogate for survival on a trial level to compare regimens in TNBC Sikov et al. SABCS 2015; von Minckwitz et al. SABCS 2015
76 Is Carboplatin Ready for Primetime in Unselected TNBC in the Adjuvant or Neoadjuvant Setting? NO Need definitive study showing improvement in DFS and/or OS If platinum is ultimately used, should it be added to standard therapy or substituted for one or more drugs? Are there triple negative subtypes that are particularly sensitive to platinum, ie biomarker driven?
77 INFORM: preop cisplatin vs AC for BRCA 1/2 carriers Schema: Randomized Phase 2: 166 patients Stage II/III BC with BRCA1 or 2 mutation AC x 4 Cis x 4 N = 170; approximately 60 enrolled S U R G E R Y Or Biopsy Additional Chemo Multicenter study Designed to show 20% improvement in pcr with cisplatin over AC B Principal Investigators: Nadine Tung and Judy Garber
78 In general, neoadjuvant therapy is preferred approach for stage II/III disease
79 Create-X: Trial Design Capecitabine for Residual Disease Eligibility: HER2- with residual disease after A- and T-containing NAC Dose: 2,500 mg/m2/day, D1-14, x 8 cycles (24 wks) DFS OS Toi et al, SABCS 2015 Masuda et al NEJM 2017
80 PI: Ingrid Mayer EA1131 Stage II/III TNBC At least 1 cm residual disease in breast after neoadjuvant Rx R A N D O M I Z E Capecitabine 1000 mg/m 2 D1-14 q3 weeks x 6 Cisplatin 75 mg/m 2 q3 weeks x 4 OR Carboplatin AUC 6 q3 weeks x 4 Stratified by PAM50 basal vs. non-basal Observation arm removed in Spring 2016
81 TNBC: Summary A disease defined by negatives is not one disease! Andrew Tutt, MD mtnbc is sensitive to a variety of standard chemotherapies, with many reasonable options Platinum chemotherapy may have a role for some mtnbc May be more active in BRCA carriers, but no evidence of superiority in sporadic Not ready for routine use in early disease PARP is a reasonable option for BRCA1/2-associated cancers with MBC Significant scientific effort has identified many new potential therapeutic targets in TNBC, and there is the promise of immunotherapy Given the limited benefit of standard cytotoxics, clinical trial participation should always be considered
Treatment of HER2+ and Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA
Treatment of HER2+ and Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Boston, USA ewiner@partners.org Disclosure Disclosure Consultant Tessaro, Leap, Genentech Off Label/Investigational
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationManagement of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Management of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Heterogeneity of TNBC Targeting TNBC by subtypes New antibody drug
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationRole of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More information(Neo-) Adjuvant chemotherapy and biological agents. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
(Neo-) Adjuvant chemotherapy and biological agents Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Neoadjuvant treatment in triple negative and HER2 positive
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationSan Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationAlternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
More informationBeyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More information